CN101495111A - 在联合治疗中使用免疫调节化合物的方法和组合物 - Google Patents

在联合治疗中使用免疫调节化合物的方法和组合物 Download PDF

Info

Publication number
CN101495111A
CN101495111A CNA2007800277224A CN200780027722A CN101495111A CN 101495111 A CN101495111 A CN 101495111A CN A2007800277224 A CNA2007800277224 A CN A2007800277224A CN 200780027722 A CN200780027722 A CN 200780027722A CN 101495111 A CN101495111 A CN 101495111A
Authority
CN
China
Prior art keywords
amino
diketone
pharmaceutically acceptable
acceptable salt
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800277224A
Other languages
English (en)
Chinese (zh)
Inventor
多米尼克·维希里
凯乐·陈
劳拉·克拉尔
劳瑞·穆塔-德帕塞维尔
海伦·布拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CN101495111A publication Critical patent/CN101495111A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CNA2007800277224A 2006-05-26 2007-05-24 在联合治疗中使用免疫调节化合物的方法和组合物 Pending CN101495111A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80860206P 2006-05-26 2006-05-26
US60/808,602 2006-05-26

Publications (1)

Publication Number Publication Date
CN101495111A true CN101495111A (zh) 2009-07-29

Family

ID=38606531

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800277224A Pending CN101495111A (zh) 2006-05-26 2007-05-24 在联合治疗中使用免疫调节化合物的方法和组合物

Country Status (11)

Country Link
EP (1) EP2023912A2 (xx)
JP (1) JP2009538318A (xx)
KR (1) KR20090014393A (xx)
CN (1) CN101495111A (xx)
AU (1) AU2007267928A1 (xx)
CA (1) CA2652888A1 (xx)
IL (1) IL195412A0 (xx)
MX (1) MX2008014912A (xx)
RU (1) RU2426542C2 (xx)
WO (1) WO2007139939A2 (xx)
ZA (1) ZA200809956B (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097120A1 (en) * 2008-01-29 2009-08-06 Celgene Corporation Methods using immunomodulatory compounds for modulating level of cd59
CA2868302A1 (en) * 2012-03-23 2013-09-26 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2754199T3 (es) * 2013-08-22 2020-04-16 Vanda Pharmaceuticals Inc Tricostatina A para el tratamiento del mieloma múltiple
CN105579101A (zh) 2013-08-22 2016-05-11 万达制药公司 癌症的治疗
JP2017511132A (ja) * 2014-03-26 2017-04-20 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
WO2015175916A1 (en) * 2014-05-16 2015-11-19 Celgene Corporation Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers
WO2023034504A1 (en) * 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
CN103393681B (zh) * 2002-05-17 2017-04-12 细胞基因公司 用于治疗和控制多发性骨髓瘤的方法及组合物
CN101108185A (zh) * 2002-10-24 2008-01-23 细胞基因公司 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CN101966183A (zh) * 2003-12-02 2011-02-09 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation

Also Published As

Publication number Publication date
RU2426542C2 (ru) 2011-08-20
EP2023912A2 (en) 2009-02-18
JP2009538318A (ja) 2009-11-05
KR20090014393A (ko) 2009-02-10
MX2008014912A (es) 2008-12-10
AU2007267928A1 (en) 2007-12-06
RU2008151713A (ru) 2010-07-10
WO2007139939A2 (en) 2007-12-06
WO2007139939A3 (en) 2008-07-03
CA2652888A1 (en) 2007-12-06
IL195412A0 (en) 2009-08-03
ZA200809956B (en) 2010-07-28

Similar Documents

Publication Publication Date Title
CN1913896B (zh) 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20080051431A1 (en) Methods and compositions using immunomodulatory compounds in combination therapy
KR100711181B1 (ko) 골수형성이상 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 이를 포함하는 조성물
CN101495111A (zh) 在联合治疗中使用免疫调节化合物的方法和组合物
KR101483802B1 (ko) 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도
CN1980667A (zh) 治疗、预防或控制不良睡眠和不良睡眠相关疾病的方法和组合物
CN101163489A (zh) 用于治疗和控制肺高血压的包含免疫调节化合物的组合物及其使用方法
CN101098694A (zh) 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
CN103025330A (zh) 使用来那度胺和阿扎胞苷的组合疗法治疗骨髓增生异常综合症的方法
KR20060124608A (ko) 석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여면역조절성 화합물을 사용하는 방법 및 이 물질을 포함하는조성물
CN101977603A (zh) 使用免疫调节化合物来调节cd59水平的方法
US20090232796A1 (en) Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
KR20050056247A (ko) 골수형성이상증후군의 치료 및 관리를 위한 선택적인사이토킨 저해 약물의 사용 방법 및 이를 포함하는 조성물
JP2009538318A5 (xx)
CN1972686A (zh) 选择性细胞因子抑制药在髓发育不良综合征中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1133198

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090729

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1133198

Country of ref document: HK